RxDoctor Payments Data

Paul Hermany, MD

Interventional Cardiology · Bethlehem, PANPI 1669784880

Payments from drug & device makers

$65,232in general payments, 2019–2025

Across 210 payments — averaging $310.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$47K
  • Medtronic$11K
  • Abbott$2K
  • Edwards Lifesciences$2K
  • Boston Scientific$1K
  • Novartis$329
  • plus $2K from 15 others

What the payments were for

  • Grants$550%
  • Travel & lodging$10,47658%
  • Food & beverage$7,68342%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,232 in reported general payments places this provider in the 75th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$215,822
Medicare patients
457
Services billed
1,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban318$396,508
JardianceEmpagliflozin55$77,953
EntrestoSacubitril/Valsartan55$65,921
XareltoRivaroxaban55$49,084
Repatha SureclickEvolocumab37$32,658
BrilintaTicagrelor13$15,804
Metoprolol Succinate393$7,466
Atorvastatin Calcium372$4,988
Ezetimibe118$3,480
Amlodipine Besylate363$2,560
Torsemide65$2,248
Rosuvastatin Calcium164$2,230
Potassium Chloride55$1,643
Carvedilol144$1,518
Losartan Potassium172$1,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$168$396,508318 claims
Boehringer IngelheimJardiance$57$77,95355 claims
NovartisEntresto$329$65,92155 claims
Johnson & JohnsonXarelto$36$49,08455 claims
AstraZenecaBrilinta$145$15,80413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →